Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
2017 · Science · 4,526 citations
https://doi.org/10.1126/science.aan4236
A
Adi Diab
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
462
Papers
22.8K
Citations
61
h-index
156
i10-index
Adi Diab is an academic researcher from University of Jordan. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 61, co-authored 393 publications.
ORCID: 0000-0002-0153-0244Papers by this author
worksManaging toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
2017 · Journal for ImmunoTherapy of Cancer · 1,913 citations
https://doi.org/10.1186/s40425-017-0300-z
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
2020 · Cancer Cell · 361 citations
https://doi.org/10.1016/j.ccell.2020.08.005
Neoadjuvant relatlimab and nivolumab in resectable melanoma
2022 · Nature · 317 citations
https://doi.org/10.1038/s41586-022-05368-8
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
2019 · Journal for ImmunoTherapy of Cancer · 289 citations
https://doi.org/10.1186/s40425-018-0478-8
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
2016 · Journal of Cutaneous Pathology · 227 citations
https://doi.org/10.1111/cup.12858
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat